Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study

被引：5

作者：

Kasudhan, Kripa Shanker ^{[1
]}

Patil, Amol N. ^{[1
]}

Jandial, Aditya ^{[2
]}

Khadwal, Alka ^{[2
]}

Prakash, Gaurav ^{[2
]}

Jain, Arihant ^{[2
]}

Bhurani, Dinesh ^{[3
]}

Ahmed, Rayaz ^{[3
]}

Agrawal, Narendra ^{[3
]}

Singh, Reema ^{[3
]}

Sachdeva, Man Updesh Singh ^{[4
]}

Varma, Neelam ^{[4
]}

Das, Reena ^{[4
]}

Verma Attri, Savita ^{[5
]}

Malhotra, Samir ^{[1
]}

Majhail, Navneet S. ^{[6
]}

Malhotra, Pankaj ^{[2
]}

Lad, Deepesh P. ^{[2
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Clin Pharmacol, Chandigarh, India

[2] Postgrad Inst Med Educ & Res, Dept Clin Hematol & Med Oncol, Chandigarh, India

[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Hematooncol, New Delhi, India

[4] Postgrad Inst Med Educ & Res, Dept Hematol, Chandigarh, India

[5] Postgrad Inst Med Educ & Res, Dept Pediat, Chandigarh, India

[6] Cleveland Clin, Dept Hematol Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 11期

关键词：

PTCy; pharmacokinetics; CEPM; GVHD; haplo-HCT; VERSUS-HOST-DISEASE; DRUG-METABOLIZING-ENZYMES; POLYMORPHISMS; SURVIVAL; GVHD; TOXICITY; REGIMEN; RELAPSE; PLASMA;

D O I：

10.1080/10428194.2022.2087067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pharmacokinetics of cyclophosphamide has been explored to optimize conditioning dosing. We hypothesized that post-transplant cyclophosphamide (PTCy) metabolite carboxy-ethyl phosphoramide mustard (CEPM) pharmacokinetics might impact haploidentical transplantation (haplo-HCT) outcomes. CEPM area under the curve (AUC(0-48)) was determined by eleven sampling timepoints on day +3/+4 using LC-MS/MS. The median CEPM AUC(0-48) in a cohort of 30 patients was 14.2 (14) mg center dot hr/L. The incidence of severe chronic graft-versus-host disease (GVHD) (73% vs. 11%, p = 0.02), and GVHD-/relapse-free survival (GRFS) was significantly inferior in the CEPM AUC(0-48) < 14 mg center dot hr/L group (54 days vs. 344 days, p = 0.02). There was, however, no difference in grade III-IV acute GVHD (38% vs. 14%, p = 0.12) and overall survival (295 days vs. not reached, p = 0.2). CEPM AUC(0-48,) is associated with severe chronic GVHD and GRFS post-haplo-HCT in this exploratory study. There is scope for personalizing day + 4 PTCy dose based on day + 3 CEPM AUC(0-8).

引用

页码：2679 / 2685

页数：7

共 27 条

[11] Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide [J].

Kanakry, Christopher G. ;

Ganguly, Sudipto ;

Zahurak, Marianna ;

Bolanos-Meade, Javier ;

Thoburn, Christopher ;

Perkins, Brandy ;

Fuchs, Ephraim J. ;

Jones, Richard J. ;

Hess, Allan D. ;

Luznik, Leo .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (211)

[12] Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant [J].

Karaesmen, Ezgi ;

Rizvi, Abbas A. ;

Preus, Leah M. ;

McCarthy, Philip L. ;

Pasquini, Marcelo C. ;

Onel, Kenan ;

Zhu, Xiaochun ;

Spellman, Stephen ;

Haiman, Christopher A. ;

Stram, Daniel O. ;

Pooler, Loreall ;

Sheng, Xin ;

Zhu, Qianqian ;

Yan, Li ;

Liu, Qian ;

Hu, Qiang ;

Webb, Amy ;

Brock, Guy ;

Clay-Gilmour, Alyssa I. ;

Battaglia, Sebastiano ;

Tritchler, David ;

Liu, Song ;

Hahn, Theresa ;

Sucheston-Campbell, Lara E. .

BLOOD, 2017, 130 (13) :1585-1596

[13] Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development [J].

Kasudhan, Kripa Shanker ;

Patial, Ajay ;

Mehra, Nancy ;

Attri, Savita Verma ;

Malhotra, Pankaj ;

Pattanaik, Smita ;

Lad, Deepesh ;

Patil, Amol N. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2022, 1198

[14] Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know [J].

Leather, HL .

BONE MARROW TRANSPLANTATION, 2004, 33 (02) :137-152

[15]

McAdams MJ, 2021, BLOOD, V138, P101

[16] Personalized Dosing of Cyclophosphamide in the Total Body Irradiation-Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy [J].

McCune, J. S. ;

Batchelder, A. ;

Guthrie, K. A. ;

Witherspoon, R. ;

Appelbaum, F. R. ;

Phillips, B. ;

Vicini, P. ;

Salinger, D. H. ;

McDonald, G. B. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (06) :615-622

[17]

McCune JS, 2016, CLIN PHARMACOKINET, V55, P525, DOI 10.1007/s40262-015-0339-2

[18] Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning [J].

McCurdy, Shannon R. ;

Radojcic, Vedran ;

Tsai, Hua-Ling ;

Vulic, Ante ;

Thompson, Elizabeth ;

Ivcevic, Sanja ;

Kanakry, Christopher G. ;

Powell, Jonathan D. ;

Lohman, Brian ;

Adom, Djamilatou ;

Paczesny, Sophie ;

Cooke, Kenneth R. ;

Jones, Richard J. ;

Varadhan, Ravi ;

Symons, Heather J. ;

Luznik, Leo .

BLOOD, 2022, 139 (04) :608-623

[19] Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant [J].

McDonald, GB ;

McCune, JS ;

Batchelder, A ;

Cole, S ;

Phillips, B ;

Ren, AG ;

Vicini, P ;

Witherspoon, R ;

Kalhorn, TF ;

Slattery, JT .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) :298-308

[20] Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation [J].

McDonald, GB ;

Slattery, JT ;

Bouvier, ME ;

Ren, S ;

Batchelder, AL ;

Kalhorn, TF ;

Schoch, HG ;

Anasetti, C ;

Gooley, T .

BLOOD, 2003, 101 (05) :2043-2048

← 1 2 3 →